Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis

• Published in: Zhonghua gan zang bing za zhi Vol. 26; no. 5; p. 353
• Main Authors: Wei, L, Wang, G Q, Sarah, J, Cheng, Q, Xie, M R, Wang, M, Xu, Z P, Duan, J L, Hou, M X, Zhang, Y X, Zhang, G, Tang, W, Zhao, S M, Lin, Z S, Jia, J J, Niu, Z L, Gao, H, Yuan, M H, Lin, X M, Zhou, J D, Luo, Yan, Linda, Fredrick, Niloufar, Mobashery, Wang, Ye, Jia, Jidong
• Format: Journal Article
• Language: Chinese
• Published: China 20-05-2018
• Subjects: Adult; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic - drug therapy; Humans; Liver Cirrhosis; Macrocyclic Compounds; Ribavirin; Ritonavir; Sulfonamides; Uracil - analogs & derivatives; Hepatitis C virus; Liver cirrhosis; Direct-acting antiviral agents
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.issn.1007-3418.2018.05.008

To evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) 25/150/100 mg once daily and dasabuvir (DSV) 250 mg twice daily combined with ribavirin in adult patients of Mainland China with chronic HCV genotype 1b infection and compensated cirrhosis.
An open-label, multicenter, phase 3 clinical trial study was conducted in mainland China, Taiwan, and South Korea. Adult patients with compensated cirrhosis (Metavir score =F4) who were newly diagnosed and treated for hepatitis C virus genotype 1b infection with ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin for 12 weeks were included. Assessed SVR rate of patients obtained at 12 and 24 weeks after drug withdrawal. Efficacy and safety were evaluated in patients who received at least one time study drugs.
A total of 63 patients from mainland China were enrolled, 62 of whom (98.4%) had a baseline Child-Pugh score of 5 points. The overall rate of SVR12 and SVR24 in patients was 100% (95% CI: 94.3% to 100.0%). Most of